WASHINGTON — Food and Drug Administration Commissioner Marty Makary has announced his resignation, with Kyle Diamantas, the agency’s leading food regulator, stepping in as acting commissioner. This leadership change occurs amid significant challenges within the FDA, raising questions about the agency’s future direction and regulatory priorities.
President Donald Trump confirmed Makary’s departure during a press briefing prior to his trip to China, remarking on Makary’s contributions and suggesting that he faced difficulties in his role. Trump’s comments underscore the pressures that FDA leadership has faced, particularly in navigating complex food safety and drug approval processes. The appointment of Diamantas, who has a robust background in food regulation, may signal a renewed focus on these critical areas.
As the FDA transitions to new leadership, industry stakeholders, including regulatory, QA/QC, and sourcing professionals, will be closely monitoring how these changes impact ongoing regulatory initiatives and the overall landscape of pharmaceutical and food safety governance.
Open the full market picture for your next decision →
